Name | DOV-216,303 Free Base |
Description | DOV-216,303 Free Base (DOV-216303) is an inhibitor of serotonin, norepinephrine, and dopamine reuptake with with IC50s of 14, 20 and 78 nM. DOV-216,303 Free Base exhibits antidepressant effects. |
In vivo | In male Sprague Dawley rats of OBX or Sham surgery, DOV 216,303 (20 mg/kg; i.p.; choronic) increases extracellular concentrations of dopamine, norepinephrine and serotonin and significantly increases extracellular baseline serotonin concentrations while DOV-216,303 (20 mg/kg; i.p.; acute) significantly increases dopamine, norepinephrine and serotonin levels[2]. |
Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
Solubility Information | DMSO : 125 mg/mL (547.96 mM) Ethanol : 95 mg/mL (416.45 mM), Sonication is recommended.
|
Keywords | inhibit | SLC6A4 | Serotonin Transporter | DOV 216303 | DOV 216,303 Free Base | DOV-216,303 Free Base | 5-HTT | DAT | DOV216303 | SERT | Dopamine Transporter | SLC6A3 | Inhibitor | DOV-216,303 | DOV216,303 Free Base |
Inhibitors Related | Olanzapine | Dapoxetine hydrochloride | CLOZAPINE N-OXIDE | Mirtazapine | Octopamine hydrochloride | Octodrine | Citicoline | Amitriptyline hydrochloride | Oxolinic acid | Mianserin hydrochloride | Fluoxetine hydrochloride | Cinchonidine |
Related Compound Libraries | Anti-Neurodegenerative Disease Compound Library | Bioactive Compound Library | Neuronal Signaling Compound Library | Antidepressant Compound Library | Membrane Protein-targeted Compound Library | ReFRAME Related Library | Neurotransmitter Receptor Compound Library | Inhibitor Library | Bioactive Compounds Library Max | GPCR Compound Library |